By modifying cysteine residues in KEAP1, oxidative stress, or electrophilic compounds like dimethyl fumarate (DMF), an FDA-approved drug for treatment of multiple sclerosis, disrupt KEAP1-NRF2 binding, leading to NRF2 accumulation20. The gene discussed is KEAP1; the disease is multiple sclerosis.